HomeCompareVMTHF vs GBDC

VMTHF vs GBDC: Dividend Comparison 2026

VMTHF yields 474.05% · GBDC yields 11.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VMTHF wins by $40739.33M in total portfolio value
10 years
VMTHF
VMTHF
● Live price
474.05%
Share price
$0.42
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40760.11M
Annual income
$28,806,329,273.60
Full VMTHF calculator →
GBDC
GBDC
● Live price
11.85%
Share price
$12.66
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.78M
Annual income
$16,389,263.41
Full GBDC calculator →

Portfolio growth — VMTHF vs GBDC

📍 VMTHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVMTHFGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VMTHF + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VMTHF pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VMTHF
Annual income on $10K today (after 15% tax)
$40,293.91/yr
After 10yr DRIP, annual income (after tax)
$24,485,379,882.56/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.11/yr
After 10yr DRIP, annual income (after tax)
$13,930,873.90/yr
At 15% tax rate, VMTHF beats the other by $24,471,449,008.66/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VMTHF + GBDC for your $10,000?

VMTHF: 50%GBDC: 50%
100% GBDC50/50100% VMTHF
Portfolio after 10yr
$20390.44M
Annual income
$14,411,359,268.50/yr
Blended yield
70.68%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

VMTHF
No analyst data
Altman Z
-0.0
Piotroski
3/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.6% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VMTHF buys
0
GBDC buys
0
No recent congressional trades found for VMTHF or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVMTHFGBDC
Forward yield474.05%11.85%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$40760.11M$20.78M
Annual income after 10y$28,806,329,273.60$16,389,263.41
Total dividends collected$39707.63M$20.36M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: VMTHF vs GBDC ($10,000, DRIP)

YearVMTHF PortfolioVMTHF Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$58,105$47,404.60$12,490$1,790.28+$45.6KVMTHF
2$319,595$257,422.91$16,522$3,157.73+$303.1KVMTHF
3$1,665,249$1,323,282.78$23,578$5,898.68+$1.64MVMTHF
4$8,225,711$6,443,893.93$37,115$11,886.75+$8.19MVMTHF
5$38,549,580$29,748,069.43$66,136$26,423.57+$38.48MVMTHF
6$171,541,094$130,293,043.94$137,257$66,491.44+$171.40MVMTHF
7$725,407,583$541,858,612.30$341,734$194,868.54+$725.07MVMTHF
8$2,917,676,445$2,141,490,330.46$1,050,788$685,133.02+$2916.63MVMTHF
9$11,171,756,198$8,049,842,402.84$4,099,314$2,974,971.01+$11167.66MVMTHF
10$40,760,108,406$28,806,329,273.60$20,775,530$16,389,263.41+$40739.33MVMTHF

VMTHF vs GBDC: Complete Analysis 2026

VMTHFStock

Venus Medtech (Hangzhou) Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally. The company's products include VenusA-Valve, a transcatheter aortic heart valve replacement (TAVR) product to treat severe aortic stenosis; VenusP-Valve is a transcatheter pulmonary valve system to treat the dysfunction of right ventricular outflow tract; V8/TAV8 balloon aortic valvuloplasty catheter systems; and TriGUARD3, a cerebral embolic protection device for minimizing the risk of brain damage and prevent cerebral embolism during TAVR and other structural heart disease surgeries. It also develops VenusA-Plus and VenusA-Pilot, which are TAVR product candidates; and transcatheter mitral and tricuspid valve replacement products; Liwen RF ablation system for the treatment of hypertrophic cardiomyopathy; and renal denervation for the treatment of hypertension. The company was founded in 2009 and is headquartered in Hangzhou, the People's Republic of China.

Full VMTHF Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this VMTHF vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VMTHF vs SCHDVMTHF vs JEPIVMTHF vs OVMTHF vs KOVMTHF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.